Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02628899 · ClinicalTrials.gov registry record · NA
Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis
A NA study of Aortic Stenosis, sponsored by Medstar Health Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 277
- Enrollment target
- 11
- Study locations
NCT02628899: Completed NA study of Aortic Stenosis, sponsored by Medstar Health Research Institute.
NCT02628899 is a NA study of Aortic Stenosis that has completed, run by Medstar Health Research Institute. The registered enrollment target is 277 participants, below the 1,352-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (80% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02628899, a NA study of Aortic Stenosis, has completed, sponsored by Medstar Health Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 277 participants
- Enrollment target
- 11
- Study locations
Study Summary
To assess the safety and feasibility of Transcatheter Aortic Valve Replacement (TAVR) with commercially available bioprostheses in patients with severe, symptomatic aortic stenosis (AS) who are low-risk (STS score ≤3%) for surgical aortic valve replacement (SAVR).
Primary Outcome
All-cause mortality at 30 days following transfemoral TACR vs. bioprosthetic SAVR
Conditions Studied
Interventions
- DEVICE SAVR
- DEVICE Transfemoral TAVR
Study Locations (11)
California
- Sutter Health System - Sacramento
- Foundation for Cardiovascular Medicine - San Diego
Virginia
- Henrico Doctors' Hospital - Richmond
- VCU Medical Center - Richmond
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Georgia
- WellStar Kennestone Hospital - Marietta
Maine
- Maine Medical Center - Portland
New Jersey
- The Valley Hospital - Ridgewood
New York
- Stony Brook Hospital - Stony Brook
Oklahoma
- St. John Health System - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2016-01 |
| Est. Completion | 2023-01 |
| Phase | NA |
What the finished NCT02628899 record still lists
NCT02628899 is an interventional study that assigns participants to a tested intervention. The registered 277 participants enrollment target is mid-sized for trials with a published cap, below the 1,352-participant average among 26 other Aortic Stenosis trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Aortic Stenosis appearing as the primary indexed condition, and to 2 interventions - of which SAVR is the first listed.
NCT02628899 lists 11 locations in 9 states (California, Virginia, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT02628899 about?
NCT02628899 is a clinical study titled "Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis". To assess the safety and feasibility of Transcatheter Aortic Valve Replacement (TAVR) with commercially available bioprostheses in patients with severe, symptomatic aortic stenosis (AS) who are low-risk (STS score ≤3%) for surgical aortic valve replacement (SAVR).
What is the current status of trial NCT02628899?
This trial is currently completed. It is a NA study. The enrollment target is 277 participants. The study started on 2016-01. Estimated completion is 2023-01.
What conditions does trial NCT02628899 study?
This clinical trial studies the following conditions: Aortic Stenosis.
What interventions are being tested in trial NCT02628899?
The interventions under investigation include: SAVR (DEVICE), Transfemoral TAVR (DEVICE).
Who is sponsoring clinical trial NCT02628899?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02628899 being conducted?
This trial has 11 study locations across California, District of Columbia, Georgia, Maine, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02628899's enrollment target sits among peer trials
277 12th of 26 higher than 15 of 26 other Aortic Stenosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aortic Stenosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Correlation Between an Impedance Cardiography Test for Decompensation and the Development of Left Ventricular Replacement Fibrosis
RECRUITING · NA
-
Evaluating Infrasonic Hemodynography
RECRUITING · NA
-
Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure
RECRUITING · NA
-
PARTNER 3 Trial - Aortic Valve-in-Valve
RECRUITING · NA
-
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
RECRUITING · NA
-
ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05818683 · 277 participants · Phase 1
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- NCT06789913 · 277 participants · Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia